Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Pancreatic Ductal Adenocarcinoma Research. Learn more about our innovative pipeline today! @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

* June 2024:- Sichuan Baili Pharmaceutical Co., Ltd.- Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma. This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.
* June 2024:- Merck Sharp & Dohme LLC- The purpose of this study is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) MK-3475A in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma or locally advanced unresectable cSCC. The primary hypothesis is that MK-3475A will result in greater than 10% objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).
* DelveInsight's Squamous Cell Carcinoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Squamous Cell Carcinoma treatment.
* The leading Squamous Cell Carcinoma Companies such as Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
* Promising Squamous Cell Carcinoma Therapies such as SI-B001, Irinotecan, Afatinib 40 MG, Pembrolizumab Injection, and others.

Stay informed about the cutting-edge advancements in Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Squamous Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Squamous Cell Carcinoma Emerging Drugs Profile

NBTXR-3: Nanobiotix

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.

mRNA-4157: Moderna Therapeutics

mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.

HB-200: Hookipa Pharma

HB-200 is HOOKIPA's lead oncology candidate engineered with the company's proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.

MCLA-158: Merus

MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.

HFB-301001: HiFiBiO

HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.

Learn more about Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Squamous Cell Carcinoma Research and development projects @ Squamous Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Squamous Cell Carcinoma Companies

Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.

Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Discover the latest advancements in Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Squamous Cell Carcinoma Pipeline Report

* Coverage- Global
* Squamous Cell Carcinoma Companies- Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
* Squamous Cell Carcinoma Therapies- SI-B001, Irinotecan, Afatinib 40 MG, Pembrolizumab Injection, and others.
* Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Squamous Cell Carcinoma Pipeline on our website @ Squamous Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/squamous-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Squamous Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Squamous Cell Carcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NBTXR-3: Nanobiotix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HB-200: Hookipa Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* HFB-301001: HiFiBiO
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Squamous Cell Carcinoma Key Companies
* Squamous Cell Carcinoma Key Products
* Squamous Cell Carcinoma- Unmet Needs
* Squamous Cell Carcinoma- Market Drivers and Barriers
* Squamous Cell Carcinoma- Future Perspectives and Conclusion
* Squamous Cell Carcinoma Analyst Views
* Squamous Cell Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=squamous-cell-carcinoma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.